Cell and Gene Therapy Biomanufacturing Market Overview
Cell and Gene Therapy Biomanufacturing Market Size was valued at USD 12.6 Billion in 2022. The Cell and Gene Therapy Biomanufacturing market industry is projected to grow from USD 13.9 Billion in 2023 to USD 31.2 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.60% during the forecast period (2024 - 2032). Growing investments in cell and gene therapy research are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Cell and Gene Therapy Biomanufacturing Market Trends
- Growing investments in cell and gene therapy manufacturing research are driving the market growth
Market CAGR for cell and gene therapy biomanufacturing is being driven by the growing investments in cell and gene therapy research. Increased funding from both the public and private sectors is fueling research efforts aimed at developing novel cell and gene therapies to address a wide range of diseases, including genetic disorders, cancer, and autoimmune diseases. This surge in research activity is creating a growing pipeline of cell and gene therapy candidates, necessitating scalable and efficient biomanufacturing processes to translate these therapies from the lab to the clinic. As a result, biomanufacturing companies are investing in innovative manufacturing platforms, automation, and process optimization to meet the increasing demand for high-quality, cost-effective cell and gene therapy products, thereby driving growth in the Cell and Gene Therapy Biomanufacturing Market.
The rapid growth of the Cell and Gene Therapy Market is propelling the Cell and Gene Therapy Biomanufacturing Market forward by creating a surge in demand for manufacturing solutions. With the approval of novel cell and gene therapies and promising clinical trial results, there is an escalating need to scale up production to meet commercialization requirements. This exponential growth in the market necessitates the development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure. Biomanufacturing companies are investing in advanced technologies, such as automation, single-use systems, and closed-system bioreactors, to address the growing demand for cell and gene therapy products. Additionally, the expansion of the market is driving collaborations, partnerships, and investments in biomanufacturing capacity, further fueling growth in the Cell and Gene Therapy Biomanufacturing Market to meet the needs of the rapidly evolving cell and gene therapy landscape.
Advancements in Cell and Gene Therapy Manufacturing Platforms are driving the Cell and Gene Therapy Biomanufacturing Market by enabling more efficient, scalable, and cost-effective production processes. Innovations in bioprocessing technologies, such as viral vector production systems, gene editing tools, and cell culture techniques, are revolutionizing biomanufacturing capabilities. These advancements allow for improved yields, enhanced product quality, and streamlined manufacturing workflows, thereby facilitating the commercialization of cell and gene therapies. Additionally, novel manufacturing platforms enable the production of complex cell and gene therapy products at a commercial scale, addressing manufacturing challenges and accelerating time-to-market. As a result, biomanufacturing companies are investing in these cutting-edge technologies to meet the growing demand for cell and gene therapy products, driving growth in the Cell and Gene Therapy Biomanufacturing Market and supporting the advancement of the cell and gene therapy industry as a whole.
For instance, Allogene Therapeutics Inc. and Antion Biosciences Inc. have established an exclusive collaboration and global license agreement concerning Antion's miRNA technology (miCAR). The objective is to advance multiplex gene silencing as an additional tool for the development of next-generation allogeneic CAR T products.
Cell and Gene Therapy Biomanufacturing Market Segment Insights
-
Cell and Gene Therapy Biomanufacturing Product Type Insights
The Cell and Gene Therapy Biomanufacturing Market segmentation, based on Product type, includes Consumables, Equipment, and Software Solutions. In 2023, the Consumables segment dominated the market, accounting for 35% of market revenue. Consumables, such as single-use bioreactors, filtration systems, and cell culture media, have captured the largest market share in the Cell and Gene Therapy Biomanufacturing Market due to their recurring need throughout the bioproduction process. These consumables are essential for cell expansion, gene modification, and product purification, driving their demand across various stages of biomanufacturing. Additionally, the adoption of disposable and single-use technologies for bioprocessing offers advantages in terms of reduced contamination risks, increased flexibility, and lower capital investment, further contributing to the dominance of consumables in the market.
Equipment product type is experiencing the highest compound annual growth rate (CAGR) in the Cell and Gene Therapy Biomanufacturing Market due to several factors. As the cell and gene therapy market expands rapidly, there is a growing demand for specialized equipment, such as bioreactors, centrifuges, and purification systems, to support manufacturing scale-up and process optimization. Additionally, advancements in bioprocessing technologies require investments in innovative equipment solutions to meet the evolving needs of biomanufacturing processes. These factors collectively contribute to the robust growth of the Equipment product type in the market.
Figure 1: Cell and Gene Therapy Biomanufacturing Market, by Product Type, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Cell and Gene Therapy Biomanufacturing Usage Insights
The Cell and Gene Therapy Biomanufacturing Market segmentation, based on Usage, includes Commercial Stage Manufacturing and Research Stage Manufacturing. In 2023, the Commercial Stage Manufacturing category generated the most income due to the increasing commercialization of cell and gene therapies. As more therapies progress through clinical trials and receive regulatory approval, there is a growing demand for large-scale manufacturing capabilities to meet commercial production needs. Commercial stage manufacturing facilities are equipped with the infrastructure and expertise required for large-scale production, making them essential for meeting the market demand for cell and gene therapy products.
Research stage manufacturing is experiencing the highest compound annual growth rate (CAGR) in the Cell and Gene Therapy Biomanufacturing Market due to the increasing focus on early-stage research and development of novel cell and gene therapies. As the field advances, there is a growing need for research-grade manufacturing facilities capable of producing small-scale batches for preclinical studies and initial clinical trials. This trend is driving investment in research stage manufacturing infrastructure and technologies to support the development of innovative cell and gene therapy candidates.
Cell and Gene Therapy Biomanufacturing Application Insights
The Cell and Gene Therapy Biomanufacturing Market segmentation, based on application, includes Upstream Processing, Harvesting, and Downstream Processing. In 2023, the Upstream Processing category generated the most income due to its critical role in cell and gene therapy production. Upstream processing involves cell culture, expansion, and modification stages, which are fundamental for generating therapeutic cells or vectors. As these processes are the initial steps in biomanufacturing, they heavily influence the quality, yield, and scalability of the final product. Consequently, there is a high demand for upstream processing technologies and equipment to optimize cell growth and gene expression, leading to the dominance of this application segment.
The Harvesting application is witnessing the highest compound annual growth rate (CAGR) in the Cell and Gene Therapy Biomanufacturing Market due to its crucial role in cell and gene therapy production processes. Harvesting involves the collection and purification of therapeutic cells or vectors from the culture medium, marking a critical step toward obtaining the final product. With the increasing demand for scalable and efficient harvesting techniques to ensure high product yields and purity, there is growing investment in innovative harvesting technologies, driving its rapid growth in the market.
Cell and Gene Therapy Biomanufacturing End User Insights
The Cell and Gene Therapy Biomanufacturing Market segmentation, based on End User, includes Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks. In 2023, the Life Science Companies category generated the most income due to their extensive involvement in the development and commercialization of cell and gene therapies. These companies possess the expertise, resources, and infrastructure required for biomanufacturing, making them key players in the market. Additionally, life science companies often have in-house manufacturing facilities or collaborate with contract development and manufacturing organizations (CDMOs) to produce cell and gene therapy products, further consolidating their dominance in the market.
Contract research organizations (CROs) end-users are experiencing the highest compound annual growth rate (CAGR) in the Cell and Gene Therapy Biomanufacturing Market due to several factors. Firstly, an increasing number of biotechnology and pharmaceutical companies are outsourcing their biomanufacturing activities to CROs to leverage their specialized expertise and infrastructure. Secondly, the rising demand for cell and gene therapy products necessitates additional manufacturing capacity, driving the need for CROs' services. Lastly, CROs offer flexible and scalable manufacturing solutions, making them attractive partners for biomanufacturing, thereby fueling their growth in the market.
Cell and Gene Therapy Biomanufacturing Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. North America has captured the largest market share in the Cell and Gene Therapy Biomanufacturing Market due to several factors. Firstly, the region boasts a robust ecosystem of biotechnology and pharmaceutical companies actively engaged in cell and gene therapy research and development. Secondly, North America has well-established regulatory frameworks and supportive policies for cell and gene therapy manufacturing, facilitating market growth. Lastly, the presence of advanced biomanufacturing infrastructure, a skilled workforce, and significant investments in research and development further contribute to the region's dominance in the market.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Cell and Gene Therapy Biomanufacturing Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Cell and Gene Therapy Biomanufacturing market accounts for the second-largest market share due to a skilled workforce. Europe has secured the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market due to several factors. The region benefits from a well-established biopharmaceutical industry, advanced infrastructure, and a skilled workforce. Additionally, Europe has favorable regulatory frameworks and supportive policies for cell and gene therapy development and manufacturing. Moreover, strategic investments in research and development, along with collaborations between industry, academia, and government institutions, contribute to Europe's significant presence in the global biomanufacturing market. Further, the German Cell and Gene Therapy Biomanufacturing market held the largest market share, and the UK Cell and Gene Therapy Biomanufacturing market was the fastest growing market in the European region.
The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is expected to grow at the fastest CAGR from 2024 to 2032. The Asia Pacific region is experiencing the highest compound annual growth rate (CAGR) in the Cell and Gene Therapy Biomanufacturing Market due to several factors. Firstly, the region's rapidly expanding biopharmaceutical industry is driven by increasing investments in research and development, particularly in cell and gene therapy. Additionally, Asia Pacific offers cost advantages for biomanufacturing operations, including lower labor and production costs. Furthermore, supportive government initiatives, favorable regulatory environments, and growing collaborations with global biopharmaceutical companies are driving the growth of the biomanufacturing market in the region. Moreover, China’s Cell and Gene Therapy Biomanufacturing market held the largest market share, and the Indian Cell and Gene Therapy Biomanufacturing market was the fastest growing market in the Asia-Pacific region.
Cell and Gene Therapy Biomanufacturing Key Market Players & Competitive Insights
Leading players are focusing on strategic initiatives to maintain their competitive edge in the cell and gene therapy biomanufacturing market. This includes investments in research and market developments to enhance bioprocessing technologies, expansion of manufacturing capabilities to meet increasing demand, and collaborations with biopharmaceutical companies to provide end-to-end biomanufacturing solutions. Furthermore, players are prioritizing regulatory compliance, quality assurance, and sustainability initiatives to ensure the production of safe and effective cell and gene therapies. Overall, these efforts aim to strengthen market position and drive innovation in biomanufacturing.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Cell and Gene Therapy Biomanufacturing industry to benefit clients and increase the market sector. In recent years, the Cell and Gene Therapy Biomanufacturing industry has offered some of the most significant advantages to consumables. Major players in the Cell and Gene Therapy Biomanufacturing market, including Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others, are attempting to increase market demand by investing in research and development operations.
Lonza Group is a leading player in the Cell and Gene Therapy Biomanufacturing Market, providing innovative solutions for the development and production of advanced therapies. With a strong global presence and decades of experience in biomanufacturing, Lonza offers a comprehensive portfolio of services and technologies tailored to the specific needs of cell and gene therapy developers. This includes expertise in cell culture, viral vector production, process development, and manufacturing scale-up. Lonza's state-of-the-art facilities and advanced bioprocessing capabilities enable the efficient and scalable production of cell and gene therapy products, supporting the translation of promising therapies from research to commercialization. Through strategic partnerships and collaborations, Lonza continues to drive innovation and advance the field of biomanufacturing in the cell and gene therapy market.
Samsung Biologics is a prominent player in the Cell and Gene Therapy Biomanufacturing Market, offering cutting-edge solutions for the development and manufacturing of biopharmaceuticals, including cell and gene therapies. Leveraging state-of-the-art facilities and advanced technologies, Samsung Biologics provides end-to-end services encompassing cell line development, process development, and cGMP manufacturing. With a focus on quality, reliability, and innovation, the company partners with biotechnology companies and pharmaceutical firms to accelerate the translation of novel therapies from concept to commercialization. Samsung Biologics' commitment to excellence, coupled with its extensive experience and expertise in biomanufacturing, positions it as a trusted partner for cell and gene therapy developers seeking scalable and cost-effective manufacturing solutions in the evolving biopharmaceutical landscape.
Key Companies in the Cell and Gene Therapy Biomanufacturing market include
- Lonza Group
- Thermo Fisher Scientific Inc.
- Merck KGaA
- WuXi AppTec
- Catalent, Inc.
- Samsung Biologics
- FUJIFILM Diosynth Biotechnologies
- Charles River Laboratories
- Cytiva
- Novasep
Cell and Gene Therapy Biomanufacturing Industry Developments
March 2023: Thermo Fisher Scientific inaugurated a cell therapy facility in collaboration with the University of California, San Francisco (UCSF) to expedite the advancement of innovative treatments for cancer, rare diseases, and various other medical conditions.
February 2022: Thermo Fisher Scientific allocated USD 40 million toward the expansion of its single-use technology manufacturing facility located in Millersburg, Pennsylvania. This initiative is a component of the company's broader investment strategy, totaling USD 650 million over several years, aimed at augmenting its capabilities to deliver adaptable, scalable, and dependable bioprocessing solutions.
Cell and Gene Therapy Biomanufacturing Market Segmentation
Cell and Gene Therapy Manufacturing Product Type Outlook
- Consumables
- Equipment
- Software Solutions
Cell and Gene Therapy Manufacturing Usage Outlook
- Commercial Stage Manufacturing
- Research Stage Manufacturing
Cell and Gene Therapy Manufacturing Application Outlook
- Upstream Processing
- Harvesting
- Downstream Processing
Cell and Gene Therapy Manufacturing End User Outlook
- Life Science Companies
- Contract Research Organizations
- Contract Manufacturing Organizations
- Cell Banks
Cell and Gene Therapy Manufacturing Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
-
Rest of the World
- Middle East
- Africa
- Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 12.6 Billion |
| Market Size 2023 |
USD 13.9 Billion |
| Market Size 2032 |
USD 31.2 Billion |
| Compound Annual Growth Rate (CAGR) |
10.60% (2024-2032) |
| Base Year |
2023 |
| Market Forecast Period |
2024-2032 |
| Historical Data |
2019- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Product Type, Usage, Application, End User, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea |
| Key Companies Profiled |
Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep and Others |
| Key Market Opportunities |
· Advanced Manufacturing Technologies and Strategic Partnerships and Collaborations |
| Key Market Dynamics |
· Growing Investments in Cell and Gene Therapy Research and Rapid Growth of the Cell and Gene Therapy Market |
Frequently Asked Questions (FAQ) :
The Cell and Gene Therapy Biomanufacturing Market size was valued at USD 13.9 Billion in 2023.
The global market is projected to grow at a CAGR of 10.60% during the forecast period, 2024-2032.
North America had the largest share in the global market.
The key players in the market are Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others.
The consumables category dominated the market in 2023.
Upstream processing had the largest share in the global market.
